Literature DB >> 9862103

E-selectin and L-selectin blockade in pure skin flaps exposed to ischaemia and reperfusion injury.

L Birk-Sørensen1, C L Kerrigan, G S Jensen.   

Abstract

The inflammatory recruitment of leucocytes is a main cause of tissue damage in ischaemia/reperfusion (I/R) injury. Under appropriate flow conditions, E-selectin and L-selectin participate in the initial deceleration of neutrophils (PMNs) on inflamed endothelial cells before transmigration of PMNs into the surrounding tissue. Previous work from our lab showed increased survival of I/R injured myocutaneous flaps after treatment with anti-E/L-selectin. In this study, we have evaluated a combined antibody to E-selectin and L-selectin (EL-246) in porcine pure skin flaps exposed to I/R injury. Buttock skin flaps were exposed to eight hours of ischaemia and 20 hours of reperfusion. EL-246 or saline was given intra-arterially into the flaps. Estimated surviving area was not improved in the treated group. The lack of effect of EL-246 supports our suspicion that different mechanisms are involved in I/R injury in myocutaneous flaps compared with pure skin flaps. As a certain shear stress must be present for the selectins to exert their effect, a possible explanation for the diverse results in muscle and skin might be different reflow patterns.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9862103     DOI: 10.1080/02844319850158444

Source DB:  PubMed          Journal:  Scand J Plast Reconstr Surg Hand Surg        ISSN: 0284-4311


  2 in total

1.  Quantitative morphodynamics of endothelial cells within confluent cultures in response to fluid shear stress.

Authors:  P Dieterich; M Odenthal-Schnittler; C Mrowietz; M Krämer; L Sasse; H Oberleithner; H J Schnittler
Journal:  Biophys J       Date:  2000-09       Impact factor: 4.033

2.  Protective effect of luteolin on skin ischemia-reperfusion injury through an AKT-dependent mechanism.

Authors:  Gang Chen; Hugang Shen; Linlin Zang; Zhonglan Su; Jilong Huang; Yong Sun; Hongwei Wang
Journal:  Int J Mol Med       Date:  2018-10-02       Impact factor: 4.101

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.